Management of Intracranial Hemorrhage

Diagnosis and Initial Management

The American Heart Association recommends obtaining a rapid non-contrast CT scan as the gold standard for confirming acute intracranial hemorrhage, with 100% sensitivity from the moment of formation 1
The American Stroke Association suggests performing baseline severity assessment using Glasgow Coma Scale (GCS) immediately, as GCS and hematoma volume are the most powerful predictors of 30-day mortality 1, 2
Consider CT angiography (CTA) within the first 3 hours if the patient presents early, as 28-38% of patients scanned within 3 hours will have hematoma expansion of >33% on follow-up imaging 3, 1, 4
CTA can identify contrast extravasation ("spot sign") within the hematoma, which predicts active bleeding and high risk of expansion 1, 4

The American Heart Association recommends rapidly correcting INR as quickly as possible using prothrombin complex concentrates (PCCs) as first-line therapy for patients on warfarin/vitamin K antagonists (VKA) 1, 5
Administer intravenous vitamin K 5-10 mg slowly as adjunct therapy (onset begins at 2 hours, maximal effect at 24 hours) for patients on warfarin/VKA 1, 4, 6
Replace specific coagulation factors for patients with congenital or acquired factor deficiencies 4, 6
Administer platelets for thrombocytopenia or qualitative platelet abnormalities 4, 6

Obtain CTA, CT venography, MRI/MRA/MRV, or catheter angiography if any of the following are present: patient factors (age <55-65 years, female sex, nonsmoker, lobar ICH location, no history of hypertension), clinical features (prodrome of headache, neurologic or constitutional symptoms before hemorrhage), or radiologic red flags 1, 4, 5, 7
Perform MR or CT venography if cerebral vein thrombosis is suspected based on hemorrhage location, relative edema volume, or abnormal signal in cerebral sinuses 1, 4, 7

Do not delay imaging or reversal of coagulopathy: active bleeding can proceed for hours after symptom onset, and two-thirds of hematoma expansion occurs within the first hour 4, 6
Do not rely on clinical features alone: it is impossible to distinguish ischemic stroke from hemorrhagic stroke based on clinical presentation; neuroimaging is mandatory 3, 7
Do not miss anticoagulated patients: 12-14% of ICH patients are on oral anticoagulants, and this proportion is increasing—always obtain medication history 4, 6, 7

Elevated systolic blood pressure >220 mmHg on admission has been associated with hematoma growth in retrospective studies, though prospective validation is limited 2
Fever >37.5°C persisting for 24 hours occurs in 83% of patients with poor outcomes and correlates with ventricular extension 2
Elevated troponin levels are associated with worse outcomes and may indicate concomitant myocardial injury 1

Hematoma expansion occurs most rapidly within the first 3 hours after intracerebral hemorrhage onset, with approximately one-third of patients demonstrating substantial expansion during this critical early period 8, 9
The highest risk of hematoma expansion occurs within the first 3 hours of bleeding onset, with 28-38% of patients scanned within this window showing subsequent expansion of >33% on follow-up imaging 10
The probability of expansion is directly influenced by how early the patient presents—earlier presentation correlates with higher likelihood of ongoing bleeding 8, 9

Shorter onset-to-CT time: Earlier imaging captures patients during the active bleeding phase 10
Larger baseline hematoma volume: Bigger initial hemorrhages have higher expansion risk 10
Anticoagulation use: Elevated INR prolongs bleeding and increases hematoma volume 11

Initial interventions targeting hematoma growth may be even more time-dependent than reperfusion therapy in ischemic stroke 8, 9
Rapid reversal of anticoagulation should occur as soon as possible, ideally within 15 minutes using prothrombin complex concentrate 11
Repeat CT imaging should be performed if neurological worsening occurs, as expansion is associated with clinical deterioration 12
Ultra-early hematoma growth (calculated by dividing baseline ICH volume by onset-to-CT interval) serves as a useful risk stratification variable 10

Hematoma expansion can continue beyond 24 hours, though at decreasing frequency 12
Repeat imaging at 24 hours is standard practice to document hemorrhage stability before certain interventions 13
The therapeutic window extends beyond expansion: Unlike the narrow window for preventing expansion, secondary injury from blood degradation products occurs over hours to weeks, providing opportunities for intervention even after the acute expansion phase 8, 9